ELIQUIS® (apixaban) Could Result in a Stroke

The FDA released the following important drug warning regarding the dangers of Eliquis, a drug that is prescribed to prevent blood clots in people who have atrial fibrillations.

WARNING: DISCONTINUING ELIQUIS IN PATIENTS WITHOUT ADEQUATE CONTINUOUS ANTICOAGULATION INCREASES RISK OF STROKE

Discontinuing ELIQUIS places patients at an increased risk of thrombotic events. An increased rate of stroke was observed following discontinuation of ELIQUIS in clinical trials in patients
with nonvalvular atrial fibrillation. If anticoagulation with ELIQUIS must be discontinued for a reason other than pathological bleeding, coverage with another anticoagulant should be strongly considered. ~FDA Boxed Warning

“Eliquis is a direct Factor Xa inhibitor approved by the FDA in December 2012 for reducing the risk of stroke and dangerous blood clots in patients with nonvalvular atrial fibrillation.”

FDA required Eliquis perform a Risk Evaluation and Mitigation Strategy (REMS) in order to properly inform healthcare providers about the serious risks associated with Eliquis, including strokes.

The dangerous drug attorneys at Zoll, Kranz & Borgess represent clients that have been injured by defective/dangerous drug and medical devices nationwide.  If you have experience harsh side effects or a stroke in result of Eliquis, contact a ZKB lawyer toll-free at (888)-841-9623. to inquire about a potential claim.